FDA Draft Guidance Seeks Faster Route for Patient-Specific Gene-Editing Therapies
The FDA issued draft guidance designed to speed personalized treatments for rare genetic diseases. Shares of gene-editing companies, including Prime Medicine, rallied Wednesday.
Shares of gene-editing companies, including Prime Medicine (PRME), rallied on Wednesday after the U.S. Food and Drug Administration issued draft guidance designed to speed personalized treatment for rare genetic diseases.Under the FDA’s new draft guidance, companies can file one application that co…